NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System
Globe Newswire•29/10/2026•08:00 ET
0
Key Highlights
- ➤14 of 15 patients were immediately pain-free after OneRF treatment
- ➤All 15 patients achieved favorable outcomes at mean six-month follow-up
- ➤53.3% of patients were pain-free without medication at last follow-up
- ➤No patient required probe repositioning to map multiple trigeminal distributions
- ➤Study was a small retrospective series without a comparison group
Expert Statements
Michael D. Staudt, MD and lead author
“In this initial series, the multi-contact probe allowed us to map and treat those distributions along a single fixed trajectory. The early pain outcomes are encouraging, and longer follow-up will help us understand the durability of relief.”
Dave Rosa, President and Chief Executive Officer of NeuroOne
“This publication adds peer-reviewed clinical evidence to our experience with OneRF for trigeminal neuralgia. We are encouraged by the pain relief reported in this initial cohort and by the ability to map and treat multiple nerve distributions without repeated probe repositioning. These findings support continued adoption of the platform and its potential to simplify the treatment workflow.”
Study Reports Immediate Pain Freedom in 14 of 15 Patients; all Patients Achieved Favorable Pain Outcomes at a Mean Six-Month Follow-Up
Multi-Contact Probe Technology Enabled Mapping and Treatment of Trigeminal Nerve Distributions without Repeated Probe Repositioning
Get started
Create a free account to read the full story.